Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain (HMX3501)
A Confirmatory, Placebo-controlled, Randomised, Double-blind, Single-dummy, Parallel Group, Ratio-finding Study in Constipated Pain Patients to Establish an Optimal Hydromorphone - Naloxone Ratio With an Improved Bowel Function and a Comparable Analgesic Efficacy Compared to Hydromorphone Alone
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Newcastle, New South Wales, Australia, 2300
- Hunter New England Area Health Service
-
-
-
-
-
Wien, Austria, A-1090
- AKH Wien - Universitätskliniken
-
-
-
-
-
Bruxelles, Belgium, 1070
- Erasme Hospital
-
-
-
-
-
Pribram, Czech Republic, 261-01
- Poradna pro lecbu bolesti
-
-
-
-
-
København K., Denmark, 1100
- Speciallæge Michael Crawford
-
-
-
-
-
Kuopio, Finland, Fl-70100
- Oma Lääkäri Oy
-
-
-
-
-
Amiens Cedex 1, France, 80054
- CHU - Hôpital Amiens Nord
-
-
-
-
-
Jena, Germany, 07747
- Universitaetsklinikum Jena
-
-
-
-
-
Tel Aviv, Israel, 64239
- Tel-Aviv Sourasky Medical Center
-
-
-
-
-
Zeist, Netherlands, 3707HL
- Diakonessenhuis, locatie Zeist
-
-
-
-
-
Krakow, Poland, 31-531
- Szpital Uniwersytecki w Krakowie Zakład Badania
-
-
-
-
-
Cluj-Napoca, Romania, 400006
- Spitalul Clinic Judetean de urgenta Cluj
-
-
-
-
-
Aarau, Switzerland, 5001
- Kantonsspital Aarau
-
-
-
-
-
Chesterfield, United Kingdom, S40 4TF
- Avondale Surgery
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects at least 18 years with a history of non-cancer or cancer pain that requires around-the-clock opioid therapy (8, 24 or 48 mg hydromorphone PR per day for the duration of the study).
- Subjects with constipation caused or aggravated by opioids
- Subjects must be willing to discontinue their current opioid analgesic routine, and .
- current laxative regimen
Exclusion Criteria:
- Chronic or intermittent pain that results from Fibromyalgia or Rheumatoid Arthritis.
- Subjects presently taking, or who have taken, naloxone <=30 days prior to the start of the Screening Period.
- Subjects suffering from diarrhoea.
- Abnormal liver or kidney function.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Bowel Function Measure Average pain scores
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Bowel Function Measures Rescue medication use
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2008-005312-18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.